SCHEMBL254869

SCHEMBL254869

Cc1n[nH]c2ccncc12

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ACHE P22303 4/20 0.46
CYP1A2 P05177 1/20 0.44
MAP2K4 P45985 1/20 0.44
FEN1 P39748 1/20 0.43
ADORA2A P29274 1/20 0.43
ADORA2B P29275 1/20 0.43
MAPT P10636 2/20 0.41
JAK2 O60674 1/20 0.41
IDO1 P14902 1/20 0.41
LRRK2 Q5S007 1/20 0.41
MKNK1 Q9BUB5 1/20 0.39
PARP1 P09874 1/20 0.38
PIM1 P11309 1/20 0.37
PDPK1 O15530 1/20 0.37
CLK2 P49760 2/20 0.37
CLK3 P49761 2/20 0.37
DYRK1A Q13627 2/20 0.37
HTR6 P50406 1/20 0.37
GRM4 Q14833 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Furan SCHEMBL16857687 0.88 CYP1A2 (0.44) ACHECYP1A2MAP2K4FEN1ADORA2A
SCHEMBL31097647 0.83 DYRK1A (0.43) ACHECYP1A2MAP2K4ADORA2AADORA2B
SCHEMBL1344802 0.83 DYRK1A (0.43) ACHECYP1A2MAP2K4ADORA2AADORA2B
SCHEMBL30269881 0.81 JAK2 (0.55) ACHEMAP2K4JAK2IDO1LRRK2
SCHEMBL5267583 0.81 JAK2 (0.55) ACHEMAP2K4JAK2IDO1LRRK2
SCHEMBL31691968 0.80 CYP1A2 (0.42) CYP1A2MAP2K4ADORA2AADORA2BJAK2
Hydrochloric Acid SCHEMBL31691957 0.79 JAK2 (0.53) ACHEMAP2K4JAK2IDO1LRRK2
SCHEMBL9258940 0.78 MKNK1 (0.57) MAP2K4MAPTJAK2IDO1LRRK2
SCHEMBL20901592 0.76 GRM4 (0.42) ACHEMAP2K4MAPTJAK2IDO1
SCHEMBL1922328 0.76 MAP2K4 (0.56) ACHEMAP2K4MAPTIDO1LRRK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250304577-A1 TYK2 INHIBITORS BIOGEN MA INC. 2025-10-02 US disclosed
EP-4583977-A1 HETEROCYCLIC DERIVATIVES AS JANUS KINASE INHIBITORS Chiesi Farmaceutici S.p.A. (IT) 2025-07-16 EP disclosed
US-20240376099-A1 COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF ENDOSOMAL TOLL-LIKE RECEPTORS NOVARTIS AG (CH) 2024-11-14 US disclosed
WO-2024215862-A2 HETEROCYCLIC COMPOUNDS AS NRAS INHIBITORS BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2024-10-17 WO disclosed
CN-115215886-B Compounds and compositions as endosomal Toll-like receptor inhibitors 诺华股份有限公司 2024-10-11 CN disclosed
US-20240279240-A1 HETEROCYCLIC DERIVATIVES AS JANUS KINASE INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2024-08-22 US disclosed
US-20240239764-A1 SUBSTITUTED AMINOBENZYL HETEROARYL COMPOUNDS AS EGFR AND/OR PI3K INHIBITORS THE REGENTS OF THE UNIVERSITY OF MICHIGAN 2024-07-18 US disclosed
US-20240209001-A1 HETEROCYCLIC DERIVATIVES AS JANUS KINASE INHIBITORS Chiesi Farmaceutici S.p. A. (IT) 2024-06-27 US disclosed
WO-2024052512-A1 HETEROCYCLIC DERIVATIVES AS JANUS KINASE INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2024-03-14 WO disclosed
US-20230312585-A1 SUBSTITUTED 4-PHENYLPIPERIDINES, THEIR PREPARATION AND USE THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2023-10-05 US disclosed
US-20100160287-A1 COMPOUNDS USEFUL AS INHIBITORS OF JANUS KINASES VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-06-24 US disclosed
US-20100160287-A1 COMPOUNDS USEFUL AS INHIBITORS OF JANUS KINASES VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-06-24 US disclosed
US-7473691-B2 Pyrazole compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-01-06 US disclosed
US-20080287444-A1 PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED 2008-11-20 US disclosed
WO-2008116139-A2 N-HETEROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF JANUS KINASES VERTEX PHARMACEUTICALS INCORPORATED (US) 2008-09-25 WO disclosed
US-7262200-B2 Indazolinone compositions useful as kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-08-28 US disclosed
EP-1318814-B1 TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS VERTEX PHARMA (US) 2007-05-30 EP disclosed
EP-1355905-B1 PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS VERTEX PHARMA (US) 2007-02-21 EP disclosed
EP-1345928-B1 PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS VERTEX PHARMA (US) 2007-02-14 EP disclosed
WO-2007015809-A2 HIV REVERSE TRANSCRIPTASE INHIBITORS MERCK & CO., INC. (US) 2007-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250304577-A1 TYK2 INHIBITORS TYK2, JAK2, JAK1 ACHE 4790/4885CYP1A2 2380/4885MAP2K4 575/4885
US-20240239764-A1 SUBSTITUTED AMINOBENZYL HETEROARYL COMPOUNDS AS EGFR AND/OR PI3K INHIBITORS EGFR, ERBB2, ERBB3 ACHE 4848/4885CYP1A2 2627/4885MAP2K4 62/4885
US-20240376099-A1 COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF ENDOSOMAL TOLL-LIKE RECEPTORS TLR3, TLR1, TLR4 ACHE 4818/4885CYP1A2 4864/4885MAP2K4 4712/4885
US-20230312585-A1 SUBSTITUTED 4-PHENYLPIPERIDINES, THEIR PREPARATION AND USE HRH4, HRH3, HRH2 ACHE 1886/4885CYP1A2 587/4885MAP2K4 1267/4885
US-20100160287-A1 COMPOUNDS USEFUL AS INHIBITORS OF JANUS KINASES JAK2, JAK1, JAK3 ACHE 4630/4885CYP1A2 4024/4885MAP2K4 614/4885
US-20240279240-A1 HETEROCYCLIC DERIVATIVES AS JANUS KINASE INHIBITORS TYK2, JAK3, JAK1 ACHE 4814/4885CYP1A2 775/4885MAP2K4 470/4885
US-20240209001-A1 HETEROCYCLIC DERIVATIVES AS JANUS KINASE INHIBITORS TYK2, JAK3, JAK1 ACHE 4815/4885CYP1A2 777/4885MAP2K4 466/4885
US-20080287444-A1 PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS AURKC, AURKA, CDK3 ACHE 1012/4885CYP1A2 1503/4885MAP2K4 113/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.